Article
Gastroenterology & Hepatology
Federico Guillermo Villamil, Nancy Elena Massenzio, Patricia Cristina Bare, Paula Andrea Cocco, Fernando Mario Cairo, Gaston Rafael Picchio
Summary: This study evaluated the impact of HCV screening, clinical evaluation, and antiviral therapy on the elimination of HCV. After 20 years of follow-up, there was a significant decrease in the prevalence of HCV in the population, and the success rate of antiviral therapy was high.
ANNALS OF HEPATOLOGY
(2022)
Article
Medicine, General & Internal
Man-Fung Yuen, Seng-Gee Lim, Robert Plesniak, Keiji Tsuji, Harry L. A. Janssen, Cristina Pojoga, Adrian Gadano, Corneliu P. Popescu, Tatyana Stepanova, Tarik Asselah, Gheorghe Diaconescu, Hyung Joon Yim, Jeong Heo, Ewa Janczewska, Alexander Wong, Nevin Idriz, Michio Imamura, Giuliano Rizzardini, Koichi Takaguchi, Pietro Andreone, Manuela Arbune, Jinlin Hou, Sung Jae Park, Andrei Vata, Jennifer Cremer, Robert Elston, Tamara Lukic, Geoff Quinn, Lauren Maynard, Stuart Kendrick, Helene Plein, Fiona Campbell, Melanie Paff, Dickens Theodore, B-Clear Study Grp
Summary: Bepirovirsen treatment for 24 weeks at a dose of 300 mg per week resulted in sustained loss of hepatitis B surface antigen (HBsAg) and HBV DNA in 9%-10% of patients with chronic HBV infection. Larger and longer trials are needed to assess the efficacy and safety of bepirovirsen.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Obstetrics & Gynecology
Sarah K. Dotters-Katz, Jeffrey A. Kuller, Brenna L. Hughes
Summary: In the United States, 1% to 4% of pregnant women are estimated to be infected with hepatitis C virus, which poses a 5% risk of transmission to infants. Regular screenings and early viral hepatitis testing for pregnant women with intrahepatic cholestasis of pregnancy are recommended to manage the risks associated with hepatitis C virus during pregnancy.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
(2021)
Article
Microbiology
Ahmed K. Oraby, Cassandra L. Gardner, Robert F. Needle, Hassan M. Kofahi, Kylie R. Everard, Nathan G. A. Taylor, Suzette G. Rutihinda, Jacqueline P. Barry, Kensuke Hirasawa, Paris E. Georghiou, Rodney S. Russell
Summary: The novel small-molecule compound AO13 demonstrated a consistent but low-level antiviral effect against HCV, potentially acting on a late stage in the viral life cycle. This compound could serve as a lead compound for future drug development against other important viruses.
MICROBIOLOGY SPECTRUM
(2021)
Article
Gastroenterology & Hepatology
Elodie Beaumont, Vincent Larochette, Laurence Preisser, Charline Miot, Pascale Pignon, Simon Blanchard, Bjorn-Thore Hansen, Jonathan Dauve, Caroline Poli, Minna M. Poranen, Patricia Lamourette, Marc Plaisance, Alain Morel, Helmut Fickenscher, Pascale Jeannin, Philippe Roingeard, Yves Delneste
Summary: IL-26 plays a crucial role in protecting against HCV infection in the liver of patients with chronic hepatitis C, exerting direct antiviral activity by inhibiting viral replication and interfering with RNA polymerase activity.
JOURNAL OF HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Jimmy C-T Lai, Vincent W-S Wong, Terry C-F Yip, Vicki W-K Hui, Yee-Kit Tse, Hye-Won Lee, Lilian Y. Liang, Grace C-Y Lui, Henry L-Y Chan, Grace L-H Wong
Summary: Over the past seventeen years, the uptake of antiviral treatment for patients with chronic hepatitis B in Hong Kong has been increasing, but there is still a proportion of patients who do not receive treatment despite meeting the criteria, mainly due to normal platelet count.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Immunology
Naglaa H. Shoukry, Andrea L. Cox, Christopher M. Walker
Summary: Controlled human infection model trials for hepatitis C virus provide an opportunity to study protective immunity and vaccine response. This article discusses immunological monitoring during such trials, including recommended sampling schedule and assays. The studies can also serve as predictors for vaccine success.
CLINICAL INFECTIOUS DISEASES
(2023)
Review
Gastroenterology & Hepatology
Chrong-Reen Wang, Hung-Wen Tsai
Summary: Human hepatitis viruses can cause liver inflammation and progress to chronic hepatitis, cirrhosis, and liver cancer, as well as complications in other organs. Vascular involvement, such as cutaneous and systemic vasculitis, is a common extrahepatic manifestation, which may be treated with antiviral therapy and corticosteroids. Therapeutic guidelines for HHV-associated vasculitis are still under development, with considerations for plasma exchange and immunosuppressive therapy in severe cases.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Immunology
Alba Rodriguez-Garcia, Maria Linares, Maria Luz Morales, Sophie Allain-Maillet, Nicolas Mennesson, Ricardo Sanchez, Rafael Alonso, Alejandra Leivas, Alfredo Perez-Rivilla, Edith Bigot-Corbel, Sylvie Hermouet, Joaquin Martinez-Lopez
Summary: This study reports on the association between HCV infection and the progression of MGUS and MM. The results suggest a causal relationship and show that antiviral treatment can lead to better disease progression. When HCV is eliminated, clonal plasma cells can be controlled, providing new possibilities for the treatment of MGUS and myeloma.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Samaa T. T. Gobran, Petronela Ancuta, Naglaa H. H. Shoukry
Summary: Coinfection of HIV and HCV significantly impacts disease progression, leading to higher viral loads and accelerated liver fibrosis progression. While DAA can cure nearly 95% of coinfected individuals, little is known about the effects on immune reconstitution and HIV reservoir.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Pharmacology & Pharmacy
Xiaomi Li, Jingyan Wang, Xiaoyan Ding, Yawen Xu, Minghua Yu, Hongxiao Wu, Na Deng, Wei Li, Jinglong Chen
Summary: The clinical efficacy of lenvatinib was compared between hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and hepatitis C virus (HCV)-related HCC. The study found that patients with HBV-HCC had higher objective response rate and disease control rate compared to HCV-HCC, but there were no significant differences in progression-free survival and overall survival between the two groups. Multivariate regression analysis identified HBV infection and antiviral time > 5 years as independent favorable factors for progression-free survival. Overall, lenvatinib seemed to be more effective in HBV-related HCC compared to HCV-related HCC.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Gastroenterology & Hepatology
Heather Valerio, Maryam Alavi, Matthew Law, Shane Tillakeratne, Janaki Amin, Naveed Z. Janjua, Mel Krajden, Jacob George, Gail Matthews, Behzad Hajarizadeh, Louisa Degenhardt, Jason Grebely, Gregory J. Dore
Summary: This study classified people with HCV based on drug dependence and found the highest treatment uptake among those with recent drug dependence, with disparities in treatment uptake related to factors such as gender, ethnicity, nationality, geographic location, among others.
JOURNAL OF HEPATOLOGY
(2021)
Article
Medicine, General & Internal
John S. Lubel, Simone I. Strasser, Alexander J. Thompson, Benjamin C. Cowie, Jennifer MacLachlan, Nicole L. Allard, Jacinta Holmes, William W. Kemp, Avik Majumdar, David Iser, Jess Howell, Gail V. Matthews
Summary: This article highlights the importance of hepatitis B infection management in Australia and provides recommendations for timely identification of patients, early initiation of antiviral therapy, and understanding the risk factors for the development of cirrhosis and hepatocellular carcinoma.
MEDICAL JOURNAL OF AUSTRALIA
(2022)
Article
Immunology
Akinbami Adenugba, Matthias Hornung, Kilian Weigand, Georg Peschel, Henrik Junger, Paul Kupke, Hauke Lang, Jens U. Marquardt, Tim Zimmermann, Edward K. Geissler, Hans J. Schlitt, Jens M. Werner
Summary: Chronic HCV infection is associated with NK cell activation and decreased IFN gamma production, with altered STAT1 and STAT4 phosphorylation. The addition of RBV to DAA therapy for HCV in LTx recipients enhances pSTAT4-dependent IFN gamma-production in NK cells.
Article
Pediatrics
Simon C. Ling, Hsing-Hua S. Lin, Karen F. Murray, Philip Rosenthal, Douglas Mogul, Norberto Rodriguez-Baez, Sarah Jane Schwarzenberg, Jeffrey Teckman, Kathleen B. Schwarz
Summary: The study found that many children with chronic HBV infection in the US and Canada remain at risk of progressive liver disease due to active hepatitis, but major clinical outcomes such as cirrhosis, cancer, and death were rare. Many children who met treatment criteria did not receive treatment.
JOURNAL OF PEDIATRICS
(2021)